These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 21342558)

  • 21. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization.
    Gandhi S; Refolo LM; Sambamurti K
    J Mol Neurosci; 2004; 24(1):137-43. PubMed ID: 15314262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
    Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
    Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors.
    Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC
    Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Docking and 3D Qsar Studies of C000000956 as a Potent Inhibitor of Bace-1.
    Joseph OA; Babatomiwa K; Niyi A; Olaposi O; Olumide I
    Drug Res (Stuttg); 2019 Aug; 69(8):451-457. PubMed ID: 30780168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.
    Saric A; Brügge Lz; Müller-Pompalla D; Rysiok T; Ousson S; Permanne B; Quattropani A; Busch M; Beher D; Hussain I
    J Biomol Screen; 2013 Mar; 18(3):277-85. PubMed ID: 23023105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
    Nawrot B
    Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for dimeric BACE-mediated APP processing.
    Jin S; Agerman K; Kolmodin K; Gustafsson E; Dahlqvist C; Jureus A; Liu G; Fälting J; Berg S; Lundkvist J; Lendahl U
    Biochem Biophys Res Commun; 2010 Feb; 393(1):21-7. PubMed ID: 20097169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking.
    Huang D; Liu Y; Shi B; Li Y; Wang G; Liang G
    J Mol Graph Model; 2013 Sep; 45():65-83. PubMed ID: 24004830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.
    Netzer WJ; Bettayeb K; Sinha SC; Flajolet M; Greengard P; Bustos V
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1389-1394. PubMed ID: 28115709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.
    Campagna J; Vadivel K; Jagodzinska B; Jun M; Bilousova T; Spilman P; John V
    J Mol Biol; 2018 May; 430(11):1566-1576. PubMed ID: 29649434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
    Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
    Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BACE-1 Inhibitors Targeting Alzheimer's Disease.
    Monteiro KLC; Dos Santos Alcântara MG; Freire NML; Brandão EM; do Nascimento VL; Dos Santos Viana LM; de Aquino TM; da Silva-Júnior EF
    Curr Alzheimer Res; 2023; 20(3):131-148. PubMed ID: 37309767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
    Semighini EP
    Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors.
    Di Pietro O; Juárez-Jiménez J; Muñoz-Torrero D; Laughton CA; Luque FJ
    PLoS One; 2017; 12(5):e0177683. PubMed ID: 28505196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.
    Jämsä A; Belda O; Edlund M; Lindström E
    J Biomed Sci; 2011 Oct; 18(1):76. PubMed ID: 22018341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of consensus scoring and principal component analysis for virtual screening against β-secretase (BACE-1).
    Liu S; Fu R; Zhou LH; Chen SP
    PLoS One; 2012; 7(6):e38086. PubMed ID: 22701601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
    Kumar A; Srivastava G; Negi AS; Sharma A
    J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors.
    Mancini F; Naldi M; Cavrini V; Andrisano V
    Anal Bioanal Chem; 2007 Jul; 388(5-6):1175-83. PubMed ID: 17541560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
    Boddapati S; Levites Y; Sierks MR
    J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE.
    Niu M; Hu J; Wu S; Xiaoe Z; Xu H; Zhang Y; Zhang J; Yang Y
    Chem Biol Drug Des; 2014 Jan; 83(1):81-8. PubMed ID: 24516878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.